Meltix0.5 mg+10 mg

Meltix 0.5 mg+10 mg is a fixed-dose combination antidepressant used to treat mild-to-moderate depression accompanied by anxiety, apathy, and low energy. It combines a low-dose antipsychotic (flupentixol) with a tricyclic antidepressant (melitracen) to produce a rapid-onset, dual-action effect on mood and motivation.

This combination is indicated for:

• Anxiety and depression occurring together
• Depressive neuroses
• Psychogenic depression
• Masked depression (depression presenting mainly with physical symptoms)
• Apathy and lack of motivation associated with depressive states
• Psychosomatic disorders accompanied by anxiety and apathy
• Menopausal depression
• Dysphoria and depression in patients recovering from alcohol or drug dependence

It is generally reserved for mild-to-moderate depressive symptoms rather than severe major depressive disorder, and is not intended for long-term maintenance therapy of chronic depression.

Combined anxiolytics & anti-depressant drugs

Meltix 0.5 mg+10 mg combines two pharmacologically distinct agents that work together to relieve depression, anxiety, and apathy through complementary mechanisms.

Flupentixol is a thioxanthene-derivative antipsychotic. At the low doses used in this combination, it blocks presynaptic dopamine D2 autoreceptors more than postsynaptic receptors, which increases dopaminergic transmission and produces a mild antidepressant, anxiolytic, and activating (energizing) effect rather than the sedative or antipsychotic effect seen at higher doses.

Melitracen is a tricyclic antidepressant (dibenzocycloheptene derivative) that inhibits the reuptake of serotonin and noradrenaline (norepinephrine) at the synaptic cleft, increasing the availability of these neurotransmitters. It has a bipolar action — stimulating at low doses and mildly sedating at higher doses — with fewer anticholinergic and cardiovascular effects than older tricyclics such as amitriptyline.

Together, these two compounds produce a preparation with antidepressant, anxiolytic, and activating properties, making it useful for depressive states dominated by apathy, fatigue, and low drive rather than agitation.

Pharmacokinetics:

Co-administration of flupentixol and melitracen does not significantly alter the individual pharmacokinetic profile of either compound, so no dose adjustment is needed purely on the basis of drug interaction between the two active ingredients themselves.

Meltix 0.5 mg+10 mg can interact with several classes of medications and substances. Always inform your doctor about all medicines, supplements, and herbal products you are taking.

Because melitracen has tricyclic-antidepressant-like properties, caution is also advised with other drugs that prolong the QT interval or have anticholinergic effects, as additive effects may occur. Concomitant use with other CNS-active or sedating medicines should be supervised by a physician.

At the recommended therapeutic doses, side effects of Meltix 0.5 mg+10 mg are generally uncommon and mild. The most frequently reported effects include:

• Transient restlessness
• Insomnia or difficulty sleeping, particularly if taken later in the day

Less commonly, patients may experience effects related to the individual components, such as:

• Dry mouth or mild anticholinergic symptoms (from melitracen)
• Dizziness or lightheadedness
• Mild tremor or extrapyramidal symptoms (from flupentixol), especially at higher doses
• Changes in appetite

Patients should seek immediate medical attention if they experience sudden mood changes, worsening depression, suicidal thoughts, palpitations, or signs of an allergic reaction.

Meltix 0.5 mg+10 mg should preferably be avoided during pregnancy, as safety data in pregnant women is limited and both components cross the placenta.

The combination should also be avoided during breastfeeding, since flupentixol and melitracen are excreted into breast milk and may affect the nursing infant.

Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with their physician before starting or continuing this medicine, and alternative treatment options should be considered where possible.

• Patients previously treated with sedative tranquillizers should have these withdrawn gradually rather than abruptly when starting this combination.
• Use with caution in patients with a history of seizures, as tricyclic-type agents may lower the seizure threshold.
• Use with caution in patients with cardiovascular disease, as melitracen's tricyclic-like activity may affect cardiac conduction.
• May cause drowsiness or reduced alertness — patients should avoid driving or operating heavy machinery until they know how the medicine affects them.
• Alcohol should be avoided, as it can intensify sedation and CNS depression.
• Monitor blood glucose regularly, as the combination may affect blood sugar levels.
• Inform the physician about any history of liver disease, thyroid disorder, severe heart disease, or urinary retention/urinary disorders before starting treatment.
• Inform the surgical team about use of this medicine before undergoing any surgical procedure or general anesthesia.
• Watch for signs of worsening depression or emergence of suicidal thoughts, particularly during the first few weeks of treatment or after dose changes.

In overdose, symptoms are typically dominated by the anticholinergic effects of melitracen, such as dry mouth, blurred vision, urinary retention, tachycardia, confusion, and drowsiness. Extrapyramidal symptoms related to flupentixol (such as muscle stiffness or tremor) may also occur, though less commonly.

Management is mainly symptomatic and supportive:

• Gastric lavage should be performed as soon as possible after ingestion.
• Activated charcoal may be administered to reduce further drug absorption.
• Respiratory and cardiovascular support should be provided as needed (monitoring of heart rhythm and blood pressure is important).
• Epinephrine (adrenaline) must not be used to treat hypotension in overdose, as it can paradoxically worsen blood pressure drop.
• Convulsions may be treated with diazepam.
• Extrapyramidal symptoms may be treated with biperiden.

Any suspected overdose requires urgent medical attention and hospital observation, including cardiac monitoring, due to the tricyclic component's potential cardiotoxicity.

Store at a temperature not exceeding 30°C in a dry place, protected from light. Keep out of the reach and sight of children.

• Elderly: Lower doses are recommended (typically 1 tablet each morning) due to increased sensitivity to sedative and anticholinergic effects and reduced drug clearance.
• Children and adolescents: Not recommended, as safety and efficacy have not been established in this age group.
• Renal impairment: Use with caution; dose adjustment may be required, and patients should be monitored closely.
• Hepatic impairment: Use with caution, as reduced hepatic metabolism may increase drug exposure and the risk of side effects.
• Cardiac disease: Should be avoided in patients recovering from a recent myocardial infarction or with bundle-branch conduction defects; used cautiously in other cardiac conditions.

Combined anxiolytics & anti-depressant drugs

This consists of two well known and well proven compounds: flupentixol-a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses, and melitracen-a bipolar thymoleptic with activating properties in low doses. In combination the compounds render a preparation with antidepressant, anxiolytic and activating properties. Maximal serum concentration is reached in about 4 hours after oral administration of flupentixol and in about 4 hours after oral administration of melitracen. The biological half-life of flupentixol is about 35 hours and that of melitracen is about 19 hours. The combination of Meltix 0.5 mg+10 mg does not seem to influence the pharmacokinetic properties of the individual compounds.

This tablet should preferably not be given during pregnancy and lactation.